NJ Biopharmaceuticals

NJ Bio is a US-based, private CRO/CDMO that has strategically positioned itself as a specialist in the rapidly growing field of complex bioconjugates and next-generation therapeutics. The company provides a fully integrated suite of services spanning early-stage discovery, translational research (in vitro/in vivo studies), process development, analytical characterization, and GMP manufacturing, primarily for oncology and infectious disease applications. Its deep expertise in ADC linker-payload chemistry, oligonucleotide synthesis, and bioconjugation makes it a critical partner for biopharma companies, from early-stage ventures to midsize and large biotechs, as evidenced by strong client testimonials. The company appears to be revenue-generating, operating as a service provider rather than developing its own therapeutic assets.

Integrated suite of capabilities in advanced bioconjugation chemistry (for ADCs, AOCs), oligonucleotide/mRNA synthesis, translational research models (CDX, PDX, humanized mouse), and GMP manufacturing for complex biologics.

NJ Bio competes in the specialized CRO/CDMO segment for complex biologics, facing competition from other niche chemistry-focused CDMOs (e.g., Cerbios-Pharma, Sterling Pharma Solutions' ADC unit) and the specialized service arms of larger CDMOs (e.g., Lonza, Catalent, Samsung Biologics). Its differentiation lies in its deep, integrated focus on conjugation chemistry and translational research, positioning it as a strategic partner rather than a generic vendor.